Buynetmeds.com has been sent a warning letter over the sale of opoioids and weight-loss drugs without a prescription.

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is independently associated with less improvement in glucose ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

Patients regain weight after stopping weight loss drugs, long-term success may depend on lifestyle and drug choice.

The weight-loss drug Ozempic is linked to dry mouth bad breath and other oral issues Here’s what the expert says about ...

It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...

A new study from Mass Eye and Ear suggests that people taking semaglutide, a drug sold as Ozempic and Wegovy, may have a ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five ...